A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2002
10/28/2002	EP1009417A4 Dietary supplements containing natural ingredients
10/25/2002	EP1017376A4 Method of treating heart failure
10/24/2002	WO2002084298A2 Medicaments which are modulators of hm74 and/or hm74a activity
10/24/2002	WO2002084288A2 Individualization of therapy with antiarrhythmics
10/24/2002	WO2002084281A1 Encapsulated cell indicator system
10/24/2002	WO2002083950A1 Methods and compositions for treating cardiovascular disease using 10218
10/24/2002	WO2002083898A1 Full-length human cdnas encoding potentially secreted proteins
10/24/2002	WO2002083879A2 Immunotherapy based on dendritic cells
10/24/2002	WO2002083874A2 Endothelial cell expression patterns
10/24/2002	WO2002083873A2 Enzymes
10/24/2002	WO2002083870A2 Pufa polyketide synthase systems and uses thereof
10/24/2002	WO2002083864A2 Methods and reagents for cell transplantation
10/24/2002	WO2002083736A2 G-protein coupled receptor molecules and uses thereof
10/24/2002	WO2002083733A2 Polynucleotides and polypeptides of the ifnalpha-6 gene
10/24/2002	WO2002083712A2 Transporters and ion channels
10/24/2002	WO2002083709A2 Kinases and phosphatases
10/24/2002	WO2002083704A1 Vascular endothelial growth factor 2
10/24/2002	WO2002083696A2 Novel cyclo azaphospha hydrocarbons
10/24/2002	WO2002083691A1 New process for the preparation of oxabispidines
10/24/2002	WO2002083690A1 New process for the preparation of oxabispidines
10/24/2002	WO2002083689A1 3,7-diazabicyclo [3.3.1] formulations as anti-arrythmic compounds
10/24/2002	WO2002083688A1 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds
10/24/2002	WO2002083687A1 3,7-diazybicyclo [3.3.1] formulations as antiarrhytmic compounds
10/24/2002	WO2002083685A1 Cyclohexylphenyl vasopressin agonists
10/24/2002	WO2002083684A1 Novel pyridine- and cyclohexenyl-comprising pyrrolobenzodiazepi ne-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists
10/24/2002	WO2002083680A1 Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
10/24/2002	WO2002083672A1 Antiviral pyrazolopyridine compounds
10/24/2002	WO2002083671A1 Mercaptoacetylamide derivatives, a process for their preparation and their use
10/24/2002	WO2002083668A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	WO2002083667A2 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	WO2002083666A1 Substituted benzofuran-2-carboxamides derivatives
10/24/2002	WO2002083664A1 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083663A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083658A1 Piperazine-benzamide derivatives useful as apob-100 and/or mtp inhibitor
10/24/2002	WO2002083650A1 Novel sulfonylamino-pyrimidines
10/24/2002	WO2002083643A1 Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors
10/24/2002	WO2002083642A1 Compounds useful as anti-inflammatory agents
10/24/2002	WO2002083640A1 Nicotinic acetylcholine receptor ligands
10/24/2002	WO2002083632A1 Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae
10/24/2002	WO2002083630A1 Oxalic acid derivatives
10/24/2002	WO2002083628A1 1,4-disubstituted benzo-fused compounds
10/24/2002	WO2002083627A2 Ligands des integrins avss6
10/24/2002	WO2002083624A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
10/24/2002	WO2002083616A1 α-SUBSTITUTED φ-ARYLFATTY ACID DERIVATIVE
10/24/2002	WO2002083186A1 Nuclear receptor-mediated introduction of a pna into cell nuclei
10/24/2002	WO2002083179A2 Fusion proteins
10/24/2002	WO2002083177A1 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine
10/24/2002	WO2002083174A1 Method of administering substance to left ventricle
10/24/2002	WO2002083161A1 Use of the protein uk114 or of fragments thereof for the treatment and prevention of the endotoxic shock
10/24/2002	WO2002083159A1 Palliative effects of morinda citrifolia oil and juice
10/24/2002	WO2002083158A1 Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles
10/24/2002	WO2002083147A1 Use of bile acid or bile salt fatty acid conjugates
10/24/2002	WO2002083143A1 Cxcr3 antagonists
10/24/2002	WO2002083137A1 Use of npy y2 receptor antagonists
10/24/2002	WO2002083128A1 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method
10/24/2002	WO2002083127A1 Protein modification-inhibitory compositions
10/24/2002	WO2002083122A1 Fatty alcohols and fatty acid esters useful for treatment of inflammation
10/24/2002	WO2002083111A2 Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence
10/24/2002	WO2002083103A2 Pharmaceutical product with reticulated crystalline microstructure
10/24/2002	WO2002083083A2 Pharmaceutically active compounds and methods of use
10/24/2002	WO2002083076A2 Method for inhibiting atherosclerotic plaque formation
10/24/2002	WO2002083066A2 Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
10/24/2002	WO2002066035A3 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
10/24/2002	WO2002061998A3 Access parameter adaptation and packet data resource management using detailed mobile status information
10/24/2002	WO2002057226A9 68730 and 69112 protein kinase molecules and uses therefor
10/24/2002	WO2002053140A3 New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
10/24/2002	WO2002051848A3 Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
10/24/2002	WO2002050065A3 Pyrazole compounds useful as protein kinase inhibitors
10/24/2002	WO2002040038A3 M. tuberculosis chaperonin 10 and uses thereof
10/24/2002	WO2002024659A3 Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists
10/24/2002	WO2002006462A3 Methylated nucleotide regulation of upa gene expression
10/24/2002	WO2002003972A3 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
10/24/2002	WO2002000210A3 Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
10/24/2002	WO2001077375A8 Diagnosis of diseases associated with gene regulation
10/24/2002	WO2001076568B1 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/24/2002	WO2001062793A9 Estrogen receptor beta variants and methods of detection thereof
10/24/2002	WO2001060778A9 Aspirin-triggered lipid mediators
10/24/2002	WO2001059103A9 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
10/24/2002	WO2000040247A9 2-oxy-benzoxazinone derivatives for the treatment of obesity
10/24/2002	US20020156293 Process for the preparation of zofenopril calcium salt
10/24/2002	US20020156292 Anticancer agents
10/24/2002	US20020156264 And method of using the carboxypeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in carboxypeptidase-related disorders
10/24/2002	US20020156254 Nucleotide sequences coding polypeptide for use in the treatment of stress, diabetes, cancer, inflammatory and cardiovascular disorders
10/24/2002	US20020156123 Novel pharmaceutical compositions for modulating angiogenesis
10/24/2002	US20020156113 Farnesyl transferase inhibitors; anticancer agents
10/24/2002	US20020156111 Substituted bicyclic compounds
10/24/2002	US20020156109 1,4-dihydropyridine derivative with a guaiacoxypropanolamine and/or phenoxypropanolamine moiety
10/24/2002	US20020156104 Novel pyrazole and pyrazoline substituted compounds
10/24/2002	US20020156102 Piperidine amides as modulators of chemo kine receptor activity
10/24/2002	US20020156094 Sulfonamide interleukin-1beta converting enzyme inhibitors
10/24/2002	US20020156090 Estrogen agonist/antagonist to prevente myocardial infarction or stroke, maintaining or improving vascular reactivity, treat renal failure, peripheral arterial occlusive disease, coronary artery disease, or raynaud's phenomenon
10/24/2002	US20020156089 Use of CRF antagonists and related compositions
10/24/2002	US20020156081 Pyrazolopyrimidines as therapeutic agents
10/24/2002	US20020156074 Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors
10/24/2002	US20020156071 Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors
10/24/2002	US20020156070 Felbamate derived compounds
10/24/2002	US20020156069 Benzo thiadiazine matrix metalloproteinase inhibitors
10/24/2002	US20020156067 New drug combinations
10/24/2002	US20020156061 Administering to a mammal a matrix metalloproteinase inhibiting amount of derivatives of isophthalic acid, isophthalic acid ester or isothalamide compounds to treat cancer, rheumatic arthritis atherosclerosis and osteoporosis
10/24/2002	US20020156051 Atherosclerosis and hyperlipidemia; ascorbic acid and anticholesterol agents that are 3-hydroxy-3-methyl glutaryl coenzyme-A reductase inhibitors

1 ... 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 ... 1595